AACR ANNUAL MEETING 2022
E2DG announces two posters at the 2022 AACR Annual Meeting in New Orleans highlighting our commitment to oncology innovation and our passion to build novel therapeutic strategies for cancer. For further information, click here.
BIO-Europe Meeting 2021
October, 2021
Meet us digitally at #BioEurope from Oct 25-28, 2021! Learn more about us and discuss a future partnership, please feel free to connect with us via the partnering platform. For further information, click here
Don’t miss the opportunity to read some of our 2021’s publications. Congratulations to all the team!
Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile. Sestito S, Bacci A, Chiarugi S, Runfola M, Gado F, Margheritis E, Gul S, Riveiro ME, Vazquez R, Huguet S, Manera C, Rezai K, Garau G, Rapposelli S. Eur J Med Chem.
Role of the tyrosine phosphatase SHP-2 mediating Adrenomedullin pro-angiogenic activity in solid tumors. Sigaud R, Dussault N, Berenguer-Daizé C, Delfino C, Benyahia Z, Cayol M, Parat F, Mabrouk K, Vázquez R, Riveiro ME, Metellus P, Ouafik LH. Frontiers in Oncology.
AACR Annual Meeting 2021
April, 2021
E2DG announces two e-posters at this year’s AACR Virtual Annual Meeting highlighting our total commitment to oncology innovation and our passion to build novel therapeutic strategies in cancer.
Season's Greetings & Happy New Year!
“A personal passion to make a difference in cancer therapy”
December, 2020
Our CSO, Eugenia Riveiro has been interviewed by Science me Up about her career journey and our passion to build novel therapeutic strategies in cancer. Follow this link.
Don’t miss the opportunity to read some of our 2020’s publications. Congratulations to all the team!
- Targeting adrenomedullin in oncology: a feasible strategy with potential as much more than an alternative anti-angiogenic therapy. Vázquez R, Riveiro ME, Berenguer-Daizé C, O’Kane A, Gormley J, Touzelet O, Rezai K, Bekradda M, Ouafik LH. Frontiers in Oncology
- Identifying pathophysiological bases of disease in COVID-19. Goldin C, Vázquez R, Polack F, Alvarez-Paggi, D. Transl Med Commun.
- Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant. chemotherapy. De Dosso S, Nucifora M, Sahname M, Epistolio S, Riveiro ME, Bertolini V, Bucci E, Boldorini R, Freguia S, Frattini M, Saletti P. European Review for Medical and Pharmacological Sciences.
- Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer. Civenni G, Roberto Bosotti, Andrea Timpanaro, Ramiro Vazquez, Jessica Merulla, Shusil Pandit, Simona Rossi, Domenico Albino, Allegrini S, Mitra A, Mapelli S, Vierling L, Giurdanella M, Marchetti M, Paganoni A, Rinaldi A, Losa M, Mira-Catò E, D’Antuono R, Morone D, Rezai K, D’Ambrosio G, Ouafik L’H, Mackenzie S, Riveiro ME, Cvitkovic E, Carbone G, Catapano C. Cell Metabolism.
AACR Virtual Annual Meeting 2020
Don’t miss the opportunity to cover the latest discoveries in cancer science and medicine. To get more information on this conference follow this link.
Virtual Bio Europe Spring
Don’t miss the opportunity to meet our team to discuss your project in oncology during BioSpring Conference!
To get more information on this conference follow this link.
Season's Greetings & Happy New Year!
The Swiss National Science Foundation (SNSF) awards the Tumor Biology and Experimental Therapeutics Group (IOR, Switzerland) headed by Prof. Carlo Catapano, the Department of Chemistry, Center for Life Sciences and Technologies (Bogazici University, Turkey) directed by Prof. Rana Sanyal and Early Drug Development Group (E2DG, France) for the project “Nanoparticle-based delivery and combinatorial therapies for cancer”
Project: SNSF_COST IZCOZ0_189862
Project Title: Nanoparticle-based delivery and combinatorial therapies for cancer
The treatment of patients with advanced metastatic cancer is still a clinical unmet need, however the considerable advances in the fight against cancer occurred during the last years. In the case of metastatic prostate cancer, it is important to expand the currently limited treatment options to improve the chances of disease control and long-term survival of the affected people. We have shown that combinations of multiple anticancer drugs targeting distinct cell populations of tumor cells have a highly synergic effect in experimental models of prostate cancer. This project aims at developing nanoparticle-based micellar systems for systemic delivery of the synergic drug combinations to prostate tumors. This approach aims at improving treatment efficacy and limiting toxicity by avoiding exposure of non-target tissues.
To get more information follow this link.
“Acelerating the drug discovery process” Conference, Pisa, Italy.
Our CSO, Dr. Riveiro Maria Eugenia will discuss the last improvements made in drug development with other international experts from academia and pharmaceutical companies during the conference “Accelerating the drug discovery process“.
To get more information follow this link.
E2DG forms a strategic collaboration with Fusion Antibodies to provide end-to-end service for oncology drug discovery companies.
To get more information follow this link.
BioFit 2019, Marseille, France.
Don’t miss the opportunity to meet our team to discuss your project in oncology during BioFit Conference!
To get more information on this conference follow this link.
BioEurope 2019, Hamburg, Germany.
Please contact us to organize a meeting with E2DG team during BioEurope 2019. To get more information on this conference follow this link.
1st COST Action CA17140 Conference. Riga, Latvia.
The Conference programs includes the following sessions:
– design, sythesis, scale up and GMP aspects of nanodrugs
– physico-chemical characterization of nanodrugs
– preclinical studies of nanodrugs
– clinical trials and regulatory aspects of nanomedicines.
You are all kindly invited to submit an abstract to the conference.
Don’t miss the opportunity to meet our CSO, Dr Riveiro Maria Eugenia will be participating to the COST Management Committee meeting and the Conference. To get more information on this conference follow this link.
September 10-12, 2019
NORDIC LIFE SCIENCE DAYS 2019, Malmö, Sweden.
Don’t miss the opportunity to meet our team to discuss your project in oncology during the NLS Days!
To get more information on this conference follow this link.
June 17 – 21, 2019
We are proud to announce the first week dedicated to gender equality in science, June 17 – 21 at the Institut Pasteur. Our CSO, Dr Riveiro Maria Eugenia will be participating together with other inspiring women representatives of the science, technology and innovation fields.
RESI CONFERENCE. Early stage investors and strategic partners matched with fundraising CEOS and scientist-entrepreneurs, Vienna, Austria.
Please contact us to organize a meeting with E2DG team during the RESI Conference. To get more information on this conference follow this link.
AACR ANNUAL MEETING 2019, Atlanta, United States.
Please contact us to organize a meeting with E2DG team during the AACR 2019. To get more information on this conference follow this link.
BIOTRINITY 2019, London, UK.
Please contact us to organize a meeting with E2DG team during BioTrinity Conference. To get more information on this conference follow this link.
Season's Greetings & Happy New Year!
Nano2Clinic
The COST Action “Cancer nanomedicine – from the bench to the bedside” WEBSITE now live at https://www.nano2clinic.eu
BIO-EUROPE 2018 Meeting
To get more information on this conference follow this link.
30th EORTC-NCI-AACR Meeting
To get more information on this conference follow this link.
Galien Medstart UP Meeting
E2DG selected to be part of the French delegation during the Galien Medstartup 2018 meeting, an initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry.
To get more information on this meeting follow this link.
COST Action
We are pleased to announced that E2DG is part of the Management Committee of the COST Action CA17140 “Cancer nanomedicine – from the bench to the bedside”. To get more information on this action follow this link.
COST is a unique means to European investigators to foster their ideas and initiatives openly, freely, and through collaborative efforts. COST promotes the integration and development of a myriad of scientific communities, maximizing the national investment in RDI, and contributing decisively to the knowledge in Europe.
AACR Annual Meeting
During the AACR meeting (14-18 April 2018) in Chicago, E2DG team will present a scientific poster showing our latest results on a novel BET inhibitor, NHWD-870. The poster can be visited on Sunday Apr 15, 2018 1:00-5:00 PM, McCormick Place South, Exhibit Hall A, Poster Section 37. We are looking forward meeting you in Chicago!
To get more information on this conference. follow this link.
BioFit 2017
To get more information on this conference. follow this link.
Innovations en Oncologie
To get more information on this conference. follow this link.
53rd International Conference on Medicinal Chemistry
To get more information on this conference. follow this link.
First Boston-Paris Biotechnology Summit
To get more information on this event. follow this link.
MEET2WIN 2017, Oncology Business Convention
To get more information on this event. follow this link.
AACR Annual Meeting 2017
To get more information on this conference. follow this link.
15th International Congress on Targeted Anticancer Therapies
To get more information on this conference. follow this link.
BioFIT 2016
To get more information on the BioFIT 2016 meeting, follow this link.
BIOTECH FINANCES
In these two articles published in Biotech Finances, our preclinical experts highlight several obstacles that they must face in order to succeed in the transfer Life Science knowledge into new treatments in oncology. Additionally, they provide solutions that can help to overcome these obstacles in early drug development.
20th HUMAN ANTIBODIES & HYBRIDOMAS
To get more information on the 20th HUMAN ANTIBODIES & HYBRIDOMAS conference, follow this link.
SATT National Meeting 2016
Universités AFSSI 2016
To get more information on this meeting follow this link.
ESMO 2016 Congress
E-JASA 2016: Last Trends in Immunotherapy
To get more information on the E-JASA meeting, follow this link.